Sen. Tommy Tuberville Sells Amgen Inc. (NASDAQ:AMGN) Stock

Senator Tommy Tuberville (R-Alabama) recently sold shares of Amgen Inc. (NASDAQ:AMGN). In a filing disclosed on May 15th, the Senator disclosed that they had sold between $15,001 and $50,000 in Amgen stock on April 15th.

Senator Tommy Tuberville also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of Duke Energy (NYSE:DUK) on 4/15/2025.
• Sold $15,001 – $50,000 in shares of CSX (NASDAQ:CSX) on 4/15/2025.
• Sold $1,001 – $15,000 in shares of Bristol-Myers Squibb (NYSE:BMY) on 4/15/2025.
• Sold $15,001 – $50,000 in shares of PayPal (NASDAQ:PYPL) on 4/15/2025.
• Sold $15,001 – $50,000 in shares of Constellation Brands (NYSE:STZ) on 4/15/2025.
• Sold $15,001 – $50,000 in shares of Alphabet (NASDAQ:GOOGL) on 4/15/2025.
• Sold $15,001 – $50,000 in shares of The Goldman Sachs Group (NYSE:GS) on 4/15/2025.
• Purchased $50,001 – $100,000 in shares of iShares Broad USD Investment Grade Corporate Bond ETF (NASDAQ:USIG) on 4/15/2025.
• Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 4/15/2025.
• Sold $15,001 – $50,000 in shares of Mastercard (NYSE:MA) on 4/15/2025.

Amgen Trading Up 0.3%

NASDAQ:AMGN opened at $272.41 on Friday. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The firm has a market capitalization of $146.48 billion, a price-to-earnings ratio of 36.08, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The business has a fifty day moving average price of $291.00 and a 200-day moving average price of $288.28.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.18 by $0.72. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The business had revenue of $8.15 billion during the quarter, compared to analyst estimates of $8.05 billion. During the same quarter in the prior year, the business posted $3.96 EPS. Amgen’s revenue for the quarter was up 9.4% compared to the same quarter last year. Sell-side analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be paid a $2.38 dividend. The ex-dividend date is Friday, May 16th. This represents a $9.52 annualized dividend and a dividend yield of 3.49%. Amgen’s dividend payout ratio (DPR) is 86.86%.

Institutional Investors Weigh In On Amgen

Institutional investors have recently bought and sold shares of the company. Zurich Insurance Group Ltd FI lifted its stake in shares of Amgen by 578.2% during the first quarter. Zurich Insurance Group Ltd FI now owns 123,440 shares of the medical research company’s stock worth $38,458,000 after buying an additional 105,240 shares during the period. McIlrath & Eck LLC raised its position in shares of Amgen by 43.5% in the first quarter. McIlrath & Eck LLC now owns 1,053 shares of the medical research company’s stock worth $328,000 after acquiring an additional 319 shares during the period. Semmax Financial Advisors Inc. raised its position in shares of Amgen by 6.0% in the first quarter. Semmax Financial Advisors Inc. now owns 12,604 shares of the medical research company’s stock worth $3,927,000 after acquiring an additional 712 shares during the period. Peloton Wealth Strategists raised its position in shares of Amgen by 1.8% in the first quarter. Peloton Wealth Strategists now owns 11,478 shares of the medical research company’s stock worth $3,576,000 after acquiring an additional 200 shares during the period. Finally, Ascent Group LLC increased its stake in shares of Amgen by 30.5% during the first quarter. Ascent Group LLC now owns 14,939 shares of the medical research company’s stock worth $4,655,000 after purchasing an additional 3,491 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

AMGN has been the subject of a number of analyst reports. UBS Group reiterated a “neutral” rating and issued a $315.00 price target (down previously from $319.00) on shares of Amgen in a research note on Friday, May 2nd. Wells Fargo & Company reissued an “equal weight” rating on shares of Amgen in a report on Wednesday, February 5th. Johnson Rice set a $294.00 price objective on shares of Amgen in a report on Wednesday, March 5th. Piper Sandler dropped their price objective on shares of Amgen from $329.00 to $328.00 and set an “overweight” rating for the company in a report on Friday. Finally, Bank of America increased their price objective on shares of Amgen from $275.00 to $294.00 and gave the company an “underperform” rating in a report on Wednesday, March 5th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $310.18.

Insider Transactions at Amgen

In related news, EVP David M. Reese sold 25,225 shares of the company’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the sale, the executive vice president now owns 36,922 shares of the company’s stock, valued at approximately $11,240,533.68. This represents a 40.59% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.76% of the company’s stock.

About Senator Tuberville

Tommy Tuberville (Republican Party) (also known as Coach) is a member of the U.S. Senate from Alabama. He assumed office on January 3, 2021. His current term ends on January 3, 2027. Tuberville (Republican Party) ran for election to the U.S. Senate to represent Alabama. He won in the general election on November 3, 2020. Tuberville was head coach for several college football teams between 1995 and 2016, including at Auburn University and the University of Cincinnati. Tommy Tuberville was born in Camden, Arkansas, and lives in Auburn, Alabama. Tuberville’s career experience includes working as a studio analyst with ESPN and as the head football coach of the University of Mississippi, the University of Auburn, Texas Tech University, and the University of Cincinnati.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.